Singhal, Udit http://orcid.org/0000-0002-3928-9476
Nallandhighal, Srinivas http://orcid.org/0000-0002-9227-0168
Tosoian, Jeffrey J. http://orcid.org/0000-0002-7614-9931
Hu, Kevin
Pham, Trinh M.
Stangl-Kremser, Judith
Liu, Chia-Jen
Karim, Razeen
Plouffe, Komal R.
Morgan, Todd M. http://orcid.org/0000-0002-1140-0603
Cieslik, Marcin
Lucianò, Roberta
Shariat, Shahrokh F.
Finocchio, Nadia
Dambrosio, Lucia
Doglioni, Claudio http://orcid.org/0000-0002-4969-5216
Chinnaiyan, Arul M. http://orcid.org/0000-0001-9282-3415
Tomlins, Scott A.
Briganti, Alberto
Palapattu, Ganesh S. http://orcid.org/0000-0002-9520-0480
Udager, Aaron M. http://orcid.org/0000-0002-8254-5404
Salami, Simpa S. http://orcid.org/0000-0001-7461-7079
Funding for this research was provided by:
Prostate Cancer Foundation
Urology Care Foundation
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Article History
Received: 18 April 2023
Accepted: 8 May 2024
First Online: 21 May 2024
Competing interests
: The content is solely the responsibility of the authors and does not necessarily represent the official views of U-M Precision Health. JJT is a co-founder with minor equity interest in LynxDx, which has licensed urinary biomarkers unrelated to this project. S.A.T has received travel support from and had a sponsored research agreement with Compendia Bioscience/Life Technologies/ThermoFisher. The University of Michigan and Brigham and Women’s Hospital have been issued a patent on <i>ETS</i> gene fusions (US8969527B2 “Recurrent gene fusions in prostate cancer”) in prostate cancer on which S.A.T. and A.M.C. are co-inventors. The diagnostic field of use was licensed to Hologic/Gen-Probe, Inc., which has sublicensed rights to Roche/Ventana Medical Systems. S.A.T. has served as a consultant for and received honoraria from Janssen, AbbVie, Sanofi, Almac Diagnostics and Astellas/Medivation. S.A.T. has sponsored research agreements with Astellas and GenomeDX. S.A.T. is a co-founder and Chief Medical Officer for Strata Oncology. T.M.M. has received research funding from MDxHealth, Myriad Genetics, and GenomeDx. T.M.M. has served as a consultant for Myriad Genetics. U.S. has received research funding from Merck & Co., Inc. S.S.S. is on a study advisory committee for Bayer Pharma and has a non-sponsored research agreement with GenomeDx. The other authors have declared that no conflict of interest exists.